tiprankstipranks
pc:con05

Convergen

Convergen is a biotech company pioneering TrimTAC—next-generation bifunctional degraders that leverage TRIM21 to selectively clear pathological multimeric proteins. Founded to address unmet medical needs in neurodegenerative disease and beyond, the company combines cutting-edge academic research with industry-proven drug development expertise to advance therapies for significantly unmet medical needs.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$10M
Total Amount Raised$10M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$10M
Latest Funding Amount$10M
Latest Funding RoundSeed Round
Latest Funding RoundSeed Round
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Dec 08, 2025
Seed Round
$10.00M

Investors

Investor Name
Funding Round

Related News and Analysis